BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 36445482)

  • 41. Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
    Wintering A; Smith S; Fuh B; Rangaswami A; Dahl G; Chien M; Gruber TA; Dang J; Li LS; Lenzen A; Savelli S; Dvorak CC; Agrawal AK; Stieglitz E
    Pediatr Blood Cancer; 2022 May; 69(5):e29499. PubMed ID: 34939322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unique ethnic features of
    Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
    Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
    Pérez B; Mechinaud F; Galambrun C; Ben Romdhane N; Isidor B; Philip N; Derain-Court J; Cassinat B; Lachenaud J; Kaltenbach S; Salmon A; Désirée C; Pereira S; Menot ML; Royer N; Fenneteau O; Baruchel A; Chomienne C; Verloes A; Cavé H
    J Med Genet; 2010 Oct; 47(10):686-91. PubMed ID: 20543203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Childhood Myelodysplastic Syndrome.
    Chisholm KM; Bohling SD
    Clin Lab Med; 2023 Dec; 43(4):639-655. PubMed ID: 37865508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hereditary Predispositions to Myelodysplastic Syndrome.
    Bannon SA; DiNardo CD
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27248996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inherited bone marrow failure syndromes and germline predisposition to myeloid neoplasia: A practical approach for the pathologist.
    Li J; Bledsoe JR
    Semin Diagn Pathol; 2023 Nov; 40(6):429-442. PubMed ID: 37507252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Clara JA; Sallman DA; Padron E
    Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.
    Sahoo SS; Pastor VB; Goodings C; Voss RK; Kozyra EJ; Szvetnik A; Noellke P; Dworzak M; Starý J; Locatelli F; Masetti R; Schmugge M; De Moerloose B; Catala A; Kállay K; Turkiewicz D; Hasle H; Buechner J; Jahnukainen K; Ussowicz M; Polychronopoulou S; Smith OP; Fabri O; Barzilai S; de Haas V; Baumann I; Schwarz-Furlan S; ; Niewisch MR; Sauer MG; Burkhardt B; Lang P; Bader P; Beier R; Müller I; Albert MH; Meisel R; Schulz A; Cario G; Panda PK; Wehrle J; Hirabayashi S; Derecka M; Durruthy-Durruthy R; Göhring G; Yoshimi-Noellke A; Ku M; Lebrecht D; Erlacher M; Flotho C; Strahm B; Niemeyer CM; Wlodarski MW
    Nat Med; 2021 Oct; 27(10):1806-1817. PubMed ID: 34621053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
    Li P; Brown S; Williams M; White T; Xie W; Cui W; Peker D; Lei L; Kunder CA; Wang HY; Murray SS; Vagher J; Kovacsovics T; Patel JL
    Blood; 2022 Aug; 140(7):716-755. PubMed ID: 35671390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
    Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
    Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
    Martin ES; Ferrer A; Mangaonkar AA; Khan SP; Kohorst MA; Joshi AY; Hogan WJ; Olteanu H; Moyer AM; Al-Kali A; Tefferi A; Chen D; Wudhikarn K; Go R; Viswanatha D; He R; Ketterling R; Nguyen PL; Oliveira JL; Gangat N; Lasho T; Patnaik MM
    Am J Hematol; 2021 Nov; 96(11):1450-1460. PubMed ID: 34390506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.